PTGX
Protagonist Therapeutics, Inc.
Price Chart
Latest Quote
$112.86
+1.42 (+1.27%)
Current Price
| Previous Close | $111.44 |
| Open | $112.88 |
| Day High | $114.48 |
| Day Low | $111.28 |
| Volume | 1,533,672 |
Stock Information
| Shares Outstanding | 64.31M |
| Total Debt | $9.78M |
| Cash Equivalents | $547.79M |
| Revenue | $74.06M |
| Net Income | $-114.71M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $7.26B |
| EPS (TTM) | $-1.81 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $6.72B |
| Sales | $74.06M |
| Income | $-114.71M |
| Book/sh | $10.21 |
| Cash/sh | $8.52 |
| Employees | 131 |
Financial Ratios
| Quick Ratio | 17.51 |
| Current Ratio | 17.76 |
| Debt/Eq | 1.49 |
Returns & Margins
| ROA | -12.37% |
| ROE | -17.06% |
| Gross Margin | 100.00% |
| Operating Margin | -6.47% |
| Profit Margin | -154.88% |
Ownership
| Insider Ownership | 0.71% |
| Institutional Ownership | 125.27% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -164.84 |
| P/S | 98.00 |
| P/B | 11.06 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $118.69 |
Technical Indicators
| SMA20 | $103.19 |
| SMA50 | $102.30 |
| SMA200 | $87.50 |
| RSI | 66.36 |
| ATR | 5.0604 |
| Shares Float | 52.49M |
| Short Float | 13.40% |
| Short Ratio | 14.18 |
| Volatility | 1.83 |
| Rel Volume | 2.37 |
Performance History
| Week | +2.80% |
| Month | +14.73% |
| Quarter | +11.00% |
| 6 Months | +23.29% |
| YTD | +29.46% |
| Year | +104.42% |
| 3 Years | +287.70% |
| 5 Years | +184.71% |
| 10 Years | +864.62% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $112.86 | 1,533,700 |
| 2026-06-17 | $111.44 | 742,500 |
| 2026-06-16 | $110.64 | 504,800 |
| 2026-06-15 | $112.46 | 536,300 |
| 2026-06-12 | $109.78 | 448,900 |
| 2026-06-11 | $109.79 | 564,100 |
| 2026-06-10 | $105.77 | 770,500 |
| 2026-06-09 | $105.87 | 878,600 |
| 2026-06-08 | $98.03 | 567,700 |
| 2026-06-05 | $97.38 | 887,400 |
| 2026-06-04 | $102.79 | 658,800 |
| 2026-06-03 | $95.41 | 579,200 |
| 2026-06-02 | $93.23 | 723,600 |
| 2026-06-01 | $94.92 | 816,600 |
| 2026-05-29 | $99.56 | 597,800 |
| 2026-05-28 | $100.41 | 551,500 |
| 2026-05-27 | $102.21 | 404,800 |
| 2026-05-26 | $99.98 | 360,700 |
| 2026-05-22 | $99.19 | 393,900 |
| 2026-05-21 | $102.01 | 402,900 |
| 2026-05-20 | $100.88 | 371,700 |
| 2026-05-19 | $98.37 | 492,700 |
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
đ° Latest News
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%
Motley Fool âĸ 2026-05-30T00:47:22Z
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More
Motley Fool âĸ 2026-05-30T00:41:49Z
J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?
The Wall Street Journal âĸ 2026-05-28T21:11:00Z
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval
Motley Fool âĸ 2026-05-18T18:43:47Z
Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy?
Motley Fool âĸ 2026-05-18T18:25:44Z
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?
Motley Fool âĸ 2026-05-18T18:10:27Z
Analyst Forecasts For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Are Surging Higher
Simply Wall St. âĸ 2026-05-11T13:05:48Z
Protagonist Therapeutics, Inc. Surprised Analysts With A Profit, And Analysts Boosted Their EPS Forecasts
Simply Wall St. âĸ 2026-05-08T12:25:15Z
Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 141% One Year Surge?
Simply Wall St. âĸ 2026-05-07T01:14:38Z
Protagonist Therapeutics Inc. (PTGX): Billionaire Tom Steyer Likes Upside Potential of This Stock
Insider Monkey âĸ 2026-05-02T14:49:26Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $46,016,000 | $434,433,000 | $60,000,000 | $26,581,000 |
| Operating Revenue | $46,016,000 | $434,433,000 | $60,000,000 | $26,581,000 |
| Expenses | ||||
| Total Expenses | $204,143,000 | $181,590,000 | $153,652,000 | $157,954,000 |
| Other Income Expense | $27,000 | $250,000 | $-201,000 | $-80,000 |
| Other Non Operating Income Expenses | $27,000 | $250,000 | $-201,000 | $-80,000 |
| Net Non Operating Interest Income Expense | $28,789,000 | $26,315,000 | $14,898,000 | $4,060,000 |
| Operating Expense | $204,143,000 | $181,590,000 | $153,652,000 | $157,954,000 |
| General And Administrative Expense | $44,853,000 | $43,462,000 | $33,491,000 | $31,739,000 |
| Interest Expense | - | - | - | $0 |
| Interest Expense Non Operating | - | - | - | $0 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-130,149,000 | $275,188,000 | $-78,955,000 | $-127,393,000 |
| Net Interest Income | $28,789,000 | $26,315,000 | $14,898,000 | $4,060,000 |
| Interest Income | $28,789,000 | $26,315,000 | $14,898,000 | $4,060,000 |
| Normalized Income | $-130,149,000 | $275,188,000 | $-78,955,000 | $-127,393,000 |
| Net Income From Continuing And Discontinued Operation | $-130,149,000 | $275,188,000 | $-78,955,000 | $-127,393,000 |
| Total Operating Income As Reported | $-158,127,000 | $252,843,000 | $-93,652,000 | $-131,373,000 |
| Net Income Common Stockholders | $-130,149,000 | $275,188,000 | $-78,955,000 | $-127,393,000 |
| Net Income | $-130,149,000 | $275,188,000 | $-78,955,000 | $-127,393,000 |
| Net Income Including Noncontrolling Interests | $-130,149,000 | $275,188,000 | $-78,955,000 | $-127,393,000 |
| Net Income Continuous Operations | $-130,149,000 | $275,188,000 | $-78,955,000 | $-127,393,000 |
| Pretax Income | $-129,311,000 | $279,408,000 | $-78,955,000 | $-127,393,000 |
| Interest Income Non Operating | $28,789,000 | $26,315,000 | $14,898,000 | $4,060,000 |
| Operating Income | $-158,127,000 | $252,843,000 | $-93,652,000 | $-131,373,000 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-2.05 | $4.23 | $-1.39 | $-2.60 |
| Basic EPS | $-2.05 | $4.47 | $-1.39 | $-2.60 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-156,847,000 | $253,669,000 | $-92,675,000 | $-130,339,000 |
| Reconciled Depreciation | $1,280,000 | $826,000 | $977,000 | $1,034,000 |
| EBITDA (Bullshit earnings) | $-156,847,000 | $253,669,000 | $-92,675,000 | $-130,339,000 |
| EBIT | $-158,127,000 | $252,843,000 | $-93,652,000 | $-131,373,000 |
| Diluted Average Shares | $63,573,048 | $65,077,722 | $56,763,559 | $49,042,232 |
| Basic Average Shares | $63,573,048 | $61,566,989 | $56,763,559 | $49,042,232 |
| Diluted NI Availto Com Stockholders | $-130,149,000 | $275,188,000 | $-78,955,000 | $-127,393,000 |
| Tax Provision | $838,000 | $4,220,000 | $0 | $0 |
| Research And Development | $159,290,000 | $138,128,000 | $120,161,000 | $126,215,000 |
| Selling General And Administration | $44,853,000 | $43,462,000 | $33,491,000 | $31,739,000 |
| Other Gand A | $44,853,000 | $43,462,000 | $33,491,000 | $31,739,000 |
| Total Unusual Items | - | - | - | $0 |
| Total Unusual Items Excluding Goodwill | - | - | - | $0 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $614,707,000 | $675,295,000 | $336,677,000 | $215,608,000 |
| Total Assets | $668,188,000 | $744,725,000 | $357,951,000 | $247,928,000 |
| Total Non Current Assets | $90,614,000 | $153,084,000 | $2,374,000 | $4,851,000 |
| Other Non Current Assets | $287,000 | $225,000 | $225,000 | $225,000 |
| Current Assets | $577,574,000 | $591,641,000 | $355,577,000 | $243,077,000 |
| Prepaid Assets | $5,714,000 | $4,238,000 | $3,628,000 | $5,670,000 |
| Receivables | $4,496,000 | $168,490,000 | $10,332,000 | $52,000 |
| Other Receivables | $10,000 | $248,000 | $76,000 | $42,000 |
| Accrued Interest Receivable | $4,365,000 | $3,242,000 | $256,000 | - |
| Cash Cash Equivalents And Short Term Investments | $567,364,000 | $418,913,000 | $341,617,000 | $237,355,000 |
| Cash And Cash Equivalents | $128,390,000 | $97,249,000 | $186,727,000 | $125,744,000 |
| Other Current Assets | - | - | - | $42,000 |
| Taxes Receivable | - | - | - | $0 |
| Investmentin Financial Assets | - | - | - | - |
| Restricted Cash | - | - | - | - |
| Debt | ||||
| Total Debt | $10,323,000 | $10,866,000 | $1,141,000 | $3,656,000 |
| Long Term Debt And Capital Lease Obligation | $8,040,000 | $10,356,000 | $0 | $1,141,000 |
| Current Debt And Capital Lease Obligation | $2,283,000 | $510,000 | $1,141,000 | $2,515,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $53,481,000 | $69,430,000 | $21,274,000 | $32,320,000 |
| Total Non Current Liabilities Net Minority Interest | $8,040,000 | $22,032,000 | $0 | $1,141,000 |
| Non Current Deferred Liabilities | $0 | $11,676,000 | $0 | - |
| Current Liabilities | $45,441,000 | $47,398,000 | $21,274,000 | $31,179,000 |
| Current Deferred Liabilities | $9,550,000 | $18,891,000 | $3,000 | $69,000 |
| Payables And Accrued Expenses | $20,844,000 | $16,919,000 | $13,344,000 | $23,628,000 |
| Payables | $5,524,000 | $4,378,000 | $871,000 | $4,055,000 |
| Other Payable | $185,000 | $74,000 | $99,000 | $415,000 |
| Total Tax Payable | $0 | $2,689,000 | $0 | - |
| Income Tax Payable | $0 | $2,689,000 | $0 | - |
| Accounts Payable | $5,339,000 | $1,615,000 | $772,000 | $3,640,000 |
| Equity | ||||
| Common Stock Equity | $614,707,000 | $675,295,000 | $336,677,000 | $215,608,000 |
| Total Equity Gross Minority Interest | $614,707,000 | $675,295,000 | $336,677,000 | $215,608,000 |
| Stockholders Equity | $614,707,000 | $675,295,000 | $336,677,000 | $215,608,000 |
| Gains Losses Not Affecting Retained Earnings | $641,000 | $-82,000 | $-105,000 | $-359,000 |
| Other Equity Adjustments | $641,000 | $-82,000 | $-105,000 | $-359,000 |
| Retained Earnings | $-470,671,000 | $-340,522,000 | $-615,710,000 | $-536,755,000 |
| Other | ||||
| Ordinary Shares Number | $62,577,897 | $61,035,139 | $57,708,613 | $49,339,252 |
| Share Issued | $62,577,897 | $61,035,139 | $57,708,613 | $49,339,252 |
| Tangible Book Value | $614,707,000 | $675,295,000 | $336,677,000 | $215,608,000 |
| Invested Capital | $614,707,000 | $675,295,000 | $336,677,000 | $215,608,000 |
| Working Capital | $532,133,000 | $544,243,000 | $334,303,000 | $211,898,000 |
| Capital Lease Obligations | $10,323,000 | $10,866,000 | $1,141,000 | $3,656,000 |
| Total Capitalization | $614,707,000 | $675,295,000 | $336,677,000 | $215,608,000 |
| Additional Paid In Capital | $1,084,736,000 | $1,015,898,000 | $952,491,000 | $752,722,000 |
| Capital Stock | $1,000 | $1,000 | $1,000 | $0 |
| Common Stock | $1,000 | $1,000 | $1,000 | $0 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $8,040,000 | $10,356,000 | $0 | $1,141,000 |
| Current Deferred Revenue | $9,550,000 | $18,891,000 | $3,000 | $69,000 |
| Current Capital Lease Obligation | $2,283,000 | $510,000 | $1,141,000 | $2,515,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $12,764,000 | $11,078,000 | $6,786,000 | $4,967,000 |
| Current Accrued Expenses | $15,320,000 | $12,541,000 | $12,473,000 | $19,573,000 |
| Investments And Advances | $78,638,000 | $140,252,000 | $0 | - |
| Net PPE | $11,689,000 | $12,607,000 | $2,149,000 | $4,626,000 |
| Accumulated Depreciation | $-8,315,000 | $-7,035,000 | $-6,234,000 | $-5,254,000 |
| Gross PPE | $20,004,000 | $19,642,000 | $8,383,000 | $9,880,000 |
| Leases | $2,936,000 | $2,424,000 | $963,000 | $913,000 |
| Other Properties | $15,577,000 | $15,771,000 | $6,277,000 | $7,878,000 |
| Machinery Furniture Equipment | $1,491,000 | $1,447,000 | $1,143,000 | $1,089,000 |
| Properties | $0 | $0 | $0 | $0 |
| Duefrom Related Parties Current | $121,000 | $165,000,000 | $10,000,000 | $10,000 |
| Other Short Term Investments | $438,974,000 | $321,664,000 | $154,890,000 | $111,611,000 |
| Dueto Related Parties Current | - | - | - | $69,000 |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $56,081,000 | $182,797,000 | $-70,845,000 | $-108,932,000 |
| Operating Activities | ||||
| Operating Cash Flow | $57,671,000 | $184,152,000 | $-70,236,000 | $-108,137,000 |
| Cash Flow From Continuing Operating Activities | $57,671,000 | $184,152,000 | $-70,236,000 | $-108,137,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,590,000 | $-1,355,000 | $-609,000 | $-795,000 |
| Investing Cash Flow | $-49,332,000 | $-299,483,000 | $-39,258,000 | $91,468,000 |
| Cash Flow From Continuing Investing Activities | $-49,332,000 | $-299,483,000 | $-39,258,000 | $91,468,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $0 | $132,100,000 | $14,553,000 |
| Financing Cash Flow | $22,864,000 | $25,853,000 | $170,477,000 | $18,838,000 |
| Cash Flow From Continuing Financing Activities | $22,864,000 | $25,853,000 | $170,477,000 | $18,838,000 |
| Net Other Financing Charges | $-479,000 | $-600,000 | $-769,000 | $-163,000 |
| Net Common Stock Issuance | $0 | $0 | $132,100,000 | $14,553,000 |
| Common Stock Issuance | $0 | $0 | $132,100,000 | $14,553,000 |
| Other | ||||
| Interest Paid Supplemental Data | $3,694,000 | $1,530,000 | $0 | $0 |
| End Cash Position | $128,677,000 | $97,474,000 | $186,952,000 | $125,969,000 |
| Beginning Cash Position | $97,474,000 | $186,952,000 | $125,969,000 | $123,890,000 |
| Changes In Cash | $31,203,000 | $-89,478,000 | $60,983,000 | $2,169,000 |
| Proceeds From Stock Option Exercised | $23,343,000 | $26,453,000 | $39,146,000 | $4,448,000 |
| Net Investment Purchase And Sale | $-47,742,000 | $-298,128,000 | $-38,649,000 | $92,263,000 |
| Sale Of Investment | $498,843,000 | $323,574,000 | $152,396,000 | $307,137,000 |
| Purchase Of Investment | $-546,585,000 | $-621,702,000 | $-191,045,000 | $-214,874,000 |
| Net PPE Purchase And Sale | $-1,590,000 | $-1,355,000 | $-609,000 | $-795,000 |
| Purchase Of PPE | $-1,590,000 | $-1,355,000 | $-609,000 | $-795,000 |
| Change In Working Capital | $146,209,000 | $-122,610,000 | $-19,511,000 | $-7,766,000 |
| Change In Other Working Capital | $-21,017,000 | $30,567,000 | - | $-1,601,000 |
| Change In Other Current Liabilities | $-903,000 | $-2,226,000 | $-2,743,000 | $-2,661,000 |
| Change In Payables And Accrued Expense | $5,610,000 | $7,817,000 | $-8,531,000 | $-11,500,000 |
| Change In Accrued Expense | $4,576,000 | $4,289,000 | $-5,597,000 | $-12,715,000 |
| Change In Payable | $1,034,000 | $3,528,000 | $-2,934,000 | $1,215,000 |
| Change In Account Payable | $3,723,000 | $842,000 | $-2,868,000 | $2,045,000 |
| Change In Tax Payable | $-2,689,000 | $2,689,000 | $0 | $0 |
| Change In Income Tax Payable | $-2,689,000 | $2,689,000 | $0 | $0 |
| Change In Prepaid Assets | $-2,360,000 | $-3,768,000 | $1,753,000 | $3,754,000 |
| Change In Receivables | $164,879,000 | $-155,000,000 | $-9,990,000 | $4,242,000 |
| Other Non Cash Items | $1,580,000 | $2,069,000 | $2,529,000 | $2,335,000 |
| Stock Based Compensation | $45,974,000 | $37,554,000 | $29,293,000 | $24,202,000 |
| Amortization Of Securities | $-7,223,000 | $-8,875,000 | $-4,569,000 | $-549,000 |
| Depreciation Amortization Depletion | $1,280,000 | $826,000 | $977,000 | $1,034,000 |
| Depreciation And Amortization | $1,280,000 | $826,000 | $977,000 | $1,034,000 |
| Depreciation | $1,280,000 | $826,000 | $977,000 | $1,034,000 |
| Net Income From Continuing Operations | $-130,149,000 | $275,188,000 | $-78,955,000 | $-127,393,000 |
| Effect Of Exchange Rate Changes | - | $0 | $0 | $-90,000 |
| Repayment Of Debt | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Deferred Tax | - | - | - | $0 |
| Deferred Income Tax | - | - | - | $0 |
| Issuance Of Debt | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
| Gain Loss On Sale Of PPE | - | - | - | - |
Fetched: 2026-06-20